Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

NCT04885634 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help reduce irregular heartbeats in overweight adults with atrial fibrillation.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Who can join Ages 18+ · all sexes

Timeline Started 2022-10 · est. completion 2024-11

What this study is testing ClinicalTrials.gov NCT04885634 ↗

Description as written by the study sponsor.

The purpose of this pilot study is to assess the feasibility of a double-blind, randomized placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard care compared to standard care alone.

Treatments tested

Semaglutide Injectable Product also known as Semaglutide plus lifestyle and cardiovascular risk factor management Drug

Subcutaneous injection of Semaglutide 2.4 mg once weekly
Placebo also known as Lifestyle and risk factor management alone Drug

Subcutaneous injection of volume-matched placebo once weekly

Main thing measured	Number of Participants to Complete Recruitment
Sponsor	Axel Brandes
Conditions studied	Atrial Fibrillation, Overweight and Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04885634 ↗